KR950016720A - 아밀로이드 단백질의 효과를 저해하는 방법 - Google Patents

아밀로이드 단백질의 효과를 저해하는 방법 Download PDF

Info

Publication number
KR950016720A
KR950016720A KR1019940031649A KR19940031649A KR950016720A KR 950016720 A KR950016720 A KR 950016720A KR 1019940031649 A KR1019940031649 A KR 1019940031649A KR 19940031649 A KR19940031649 A KR 19940031649A KR 950016720 A KR950016720 A KR 950016720A
Authority
KR
South Korea
Prior art keywords
compound
formula
piperidino
solvate
optionally substituted
Prior art date
Application number
KR1019940031649A
Other languages
English (en)
Inventor
헨리 워커 룬 윌리암
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016720A publication Critical patent/KR950016720A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 효과량의 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물을 아밀로이드 단백질과 관련된 생리학적 질환의 억제를 필요로 하는 인간에게 투여함을 포함하는, 상기 질환의 억제방법을 포함한다:
상기식에서,
R1및 R2는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피톨리딘, 헥사메틸렌에미노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

아밀로이드 단백질의 효과를 저해하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 과량의 아밀로이드 단백질과 관련된 생리학적 질환을 저해하는데 사용하기 위한 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  2. 제1항에 있어서,상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물:
  3. 아밀로이드 단백질의 생성을 저해하는데 사용하기 위한 하기 일반식(I)의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  4. 제3항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물:
  5. 아밀로이드 플라크의 침착을 저해하는데 사용하기 위한 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  6. 제5항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물:
  7. 알쯔하이머 질병을 저해하는데 사용하기 위한 하기 일반식(I)의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  8. 제7항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940031649A 1993-12-01 1994-11-29 아밀로이드 단백질의 효과를 저해하는 방법 KR950016720A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,379 1993-12-01
US08/160,379 US6489355B2 (en) 1993-12-01 1993-12-01 Methods of inhibiting the effects of amyloidogenic proteins

Publications (1)

Publication Number Publication Date
KR950016720A true KR950016720A (ko) 1995-07-20

Family

ID=22576649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940031649A KR950016720A (ko) 1993-12-01 1994-11-29 아밀로이드 단백질의 효과를 저해하는 방법

Country Status (14)

Country Link
US (1) US6489355B2 (ko)
EP (1) EP0663209A3 (ko)
JP (1) JPH07188010A (ko)
KR (1) KR950016720A (ko)
CN (1) CN1109750A (ko)
AU (1) AU673961B2 (ko)
CA (1) CA2136789A1 (ko)
CZ (1) CZ293194A3 (ko)
HU (1) HUT72297A (ko)
IL (1) IL111790A (ko)
NO (1) NO944577L (ko)
NZ (1) NZ270008A (ko)
UA (1) UA26459C2 (ko)
ZA (1) ZA949404B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
AU751158B2 (en) * 1998-06-16 2002-08-08 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
US8362066B2 (en) * 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
CN108186678A (zh) * 2018-01-10 2018-06-22 天津科技大学 羟基化碳纳米管在制备抑制β-淀粉样蛋白聚集的药物的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5145892A (en) * 1985-12-19 1992-09-08 Chisso Corporation Polypropylene resin composition
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US4960815A (en) * 1988-09-22 1990-10-02 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives
US5081304A (en) * 1988-09-22 1992-01-14 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9002834D0 (en) * 1990-02-08 1990-04-04 Ici America Inc Compounds
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5175164A (en) * 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5192220A (en) * 1992-01-31 1993-03-09 Amp Inc. Dual readout extended socket
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5288249A (en) * 1992-09-02 1994-02-22 Cooper Industries, Inc. Base for cartridge lamp
US5252524A (en) * 1992-10-16 1993-10-12 Corning Incorporated Polarizing glasses
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法

Also Published As

Publication number Publication date
HUT72297A (en) 1996-04-29
CA2136789A1 (en) 1995-06-02
CN1109750A (zh) 1995-10-11
EP0663209A3 (en) 1995-10-11
US20010051368A1 (en) 2001-12-13
HU9403422D0 (en) 1995-02-28
UA26459C2 (uk) 1999-08-30
NZ270008A (en) 1997-07-27
CZ293194A3 (en) 1995-07-12
US6489355B2 (en) 2002-12-03
AU673961B2 (en) 1996-11-28
NO944577D0 (no) 1994-11-29
JPH07188010A (ja) 1995-07-25
ZA949404B (en) 1996-05-28
IL111790A0 (en) 1995-01-24
IL111790A (en) 1998-10-30
EP0663209A2 (en) 1995-07-19
AU7909394A (en) 1995-06-08
NO944577L (no) 1995-06-02

Similar Documents

Publication Publication Date Title
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
ES2163425T3 (es) Uso de raloxifeno y de sus analogos para la fabricacion de un medicamento para el tratamiento de la ateroesclerosis y la enfermedad cardiaca isquemica.
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR950016729A (ko) 유방 질환의 억제 방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950016720A (ko) 아밀로이드 단백질의 효과를 저해하는 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application